NCT03979170Recruiting
Patient-derived Organoids of Lung Cancer to Test Drug Response
Summary
This is a single center, single arm, open and exploratory clinical study, with 50 cases planned for a period of 3 years. The purpose of this study is to evaluate the consistency and accuracy of a Patient-Derived Organoid (PDO) Model of lung cancer to predict the clinical efficacy of anti-cancer drugs, in order to predict the best chemotherapy regimen for each given patient.
Inclusion criteria
• Histologically proven lung cancer • Age ≥ 18 • Written informed and signed consent • Accessible to biopsy and/or surgery sample of metastasis and/or primitive tumour
Exclusion criteria
• Less than 18 years of age • Not able to give informed consent (language, intellectual capacities, etc.) • Not accessible to biopsy and/or surgery sample • Not enough lung tissue for a histological analysis or the remaining lung tissue is not enough to perform a routine pathological analysis.
Contacts
The trial team's contact details are shown on request.
See the official trial record- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Countries
- Switzerland
- Sponsor
- University Hospital, Geneva(Other)
- Protocol no.
- 2018-02395
- Conditions
- Lung Cancer, Organoid
- Interventions
- Procedure
Treatments studied
- Lung tumor resection
Locations · 1
- Geneva, SwitzerlandGeneva University HospitalsRecruiting at this site
In total, worldwide, the only site listed in the registry is recruiting.
Site status per the ClinicalTrials.gov registry (last update posted: June 3, 2024).
This status may have changed and says nothing about your eligibility: before taking any step, check with your oncologist or the site.
Other identifiers
- 2018 · NIH grant
See also
Other versions
These results are indicative and do not replace medical advice — discuss them with your doctor.